Table 7.
Ongoing trials for advanced activating epidermal growth factor receptor -mutated non-small cell lung cancer
| Line | Trial | Phase | Treatment | Primary endpoint |
| First | LUX-Lung 7 (NCT01466660) | IIb | Afatinib vs Gefitinib | PFS/OS |
| ARCHER-1050 (NCT01774721) | III | Dacomitinib vs Gefitinib | PFS | |
| Tamiya et al[65] (UMIN000005503) | II | CBDCA + TS-1 + gefitinib | PFS | |
| NEJ 009 (UMIN000006340) | III | CBDCA + PEM + gefitinib vs Gefitinib | OS | |
| Second/third | WJOG (UMIN000002014) | III | Gefitinib vs Erlotinib | PFS |
| IMPRESS (NCT01544179) | III | Continuation of gefitinib + CDDP + PEM vs CDDP+PEM | PFS | |
| JMTO12-01 (UMIN000007765) | II | Continuation of gefitinib + DOC/PEM vs DOC/PEM | PFS |
EGFR: Epidermal growth factor receptor; NSCLC: Non-small cell lung cancer; PFS: Progression-free survival; OS: Overall survival; CBDCA: Carboplatin; PEM: Pemetrexed; CDDP: Cisplatin; DOC: Docetaxel.